Publicaciones en colaboración con investigadores/as de Universitat de Barcelona (122)

2024

  1. Applicability of the Barcelona scale to assess the quality of cleanliness of mucosa at esophagogastroduodenoscopy

    Gastroenterologia y Hepatologia, Vol. 47, Núm. 3, pp. 246-252

  2. CTNND1 is involved in germline predisposition to early-onset gastric cancer by affecting cell-to-cell interactions

    Gastric Cancer, Vol. 27, Núm. 4, pp. 747-759

  3. Effectiveness of Helicobacter pylori Treatments According to Antibiotic Resistance

    American Journal of Gastroenterology, Vol. 119, Núm. 4, pp. 646-654

  4. Endoscopic surveillance for familial intestinal gastric cancer in low-incidence areas: An effective strategy

    International Journal of Cancer, Vol. 154, Núm. 1, pp. 124-132

  5. Gene content, phage cycle regulation model and prophage inactivation disclosed by prophage genomics in the Helicobacter pylori Genome Project

    Gut Microbes, Vol. 16, Núm. 1

  6. Indications of Helicobacter pylori Eradication Treatment and Its Influence on Prescriptions and Effectiveness (Hp-EuReg)

    Helicobacter, Vol. 29, Núm. 4

  7. Initial Management of Intra-abdominal Abscesses and Preventive Strategies for Abscess Recurrence in Penetrating Crohn's Disease: A National, Multicentre Study Based on ENEIDA Registry

    Journal of Crohn's & colitis, Vol. 18, Núm. 4, pp. 578-588

  8. Role of proton pump inhibitors dosage and duration in Helicobacter pylori eradication treatment: Results from the European Registry on H. pylori management

    United European Gastroenterology Journal, Vol. 12, Núm. 1, pp. 122-138

  9. Stratified analyses refine association between TLR7 rare variants and severe COVID-19

    Human Genetics and Genomics Advances, Vol. 5, Núm. 4

  10. Use of multi-gene panels in patients at high risk of hereditary digestive cancer: position statement of AEG, SEOM, AEGH and IMPaCT-GENÓMICA consortium

    Gastroenterologia y Hepatologia, Vol. 47, Núm. 3, pp. 293-318

2023

  1. A microRNA signature for risk-stratification and response prediction to FOLFOX-based adjuvant therapy in stage II and III colorectal cancer

    Molecular Cancer

  2. A second update on mapping the human genetic architecture of COVID-19

    Nature

  3. Analysis of Clinical Phenotypes through Machine Learning of First-Line H. pylori Treatment in Europe during the Period 2013–2022: Data from the European Registry on H. pylori Management (Hp-EuReg)

    Antibiotics, Vol. 12, Núm. 9

  4. Author Correction: Comparison of the management of Helicobacter pylori infection between the older and younger European populations (Scientific Reports, (2023), 13, 1, (17235), 10.1038/s41598-023-43287-4)

    Scientific Reports

  5. BMPR2 as a Novel Predisposition Gene for Hereditary Colorectal Polyposis

    Gastroenterology, Vol. 165, Núm. 1, pp. 162-172.e5

  6. Combining Asian and European genome-wide association studies of colorectal cancer improves risk prediction across racial and ethnic populations

    Nature Communications, Vol. 14, Núm. 1

  7. Comparison of the management of Helicobacter pylori infection between the older and younger European populations

    Scientific Reports, Vol. 13, Núm. 1

  8. Erratum to: Mapping the human genetic architecture of COVID-19 (Nature, (2021), 600, 7889, (472-477), 10.1038/s41586-021-03767-x)

    Nature

  9. Genome-wide epistasis study highlights genetic interactions influencing severity of COVID-19

    European Journal of Epidemiology, Vol. 38, Núm. 8, pp. 883-889

  10. Inhibition of YTHDF1 by salvianolic acid overcomes gluten-induced intestinal inflammation

    Gut